


[Contact Us](#) | [Help](#) | [Print Page](#)
[Home](#) [Search](#) [Results](#) [Queries](#)

A MEMBER OF THE **OPD**

## An Information Portal to Biological Macromolecular Structure

 As of Tuesday Jun 06, 2006 there are 36932 Structures | [PDB Statistics](#)
☒ PDB ID or keyword ☐ Author  | [Advanced Search](#)

5 Structure Hits 3 Web Page Hits 3 Unreleased Structures

- ☐ Results (1-5 of 5)
- ☐ Results ID List
- ☐ Refine this Search
- ☐ 3 Structures Awaiting Release
- ☐ Select All
- ☐ Deselect All
- ☐ Download Selected
- ☒ Tabulate
- ☒ Narrow Query
- ☒ Sort Results
- ☒ Results per Page
- ☐ Show Query Details
- Results Help

☒ 2BUB


1

### CRYSTAL STRUCTURE OF HUMAN DIPEPTIDYL PEPTIDASE IV (CD26) IN COMPLEX WITH A REVERSED AMIDE INHIBITOR

**Characteristics**

Release Date: 23-Jan-2006 Exp. Method: X Ray Diffraction

**Classification**

 Resolution: 2.66 Å  
Complex (hydrolase/inhibitor)

**Compound**

 Mol. Id: 1 Molecule: Dipeptidyl Peptidase 4 Fragment: E  
Domain Residues 39 766

**Authors**

Nordhoff, S., Cerezo-Galvez, S., Feurer, A., Hill O., Matassa, V.G., Metz, G., Rummey, C., Thien M., Edwards, P.J.

☒ 1WCY


### Crystal Structure Of Human Dipeptidyl Peptidase IV (DPP-IV) Complex With Diprotin A

**Characteristics**

Release Date: 07-May-2005 Exp. Method: X Ray Diffraction

**Classification**

 Resolution: 2.20 Å  
Hydrolase

**Compound**

 Mol. Id: 1 Molecule: Dipeptidyl Peptidase Iv Fragment: F  
772 Mol. Id: 2 Molecule: Diprotin a  
Hiramatsu, H., Yamamoto, A., Kyono, K., Higashiyama, Y., Fukushima, C., Shima, H., Sugiyama, S., Inoue, K., Shimizu, R.

**Authors**
☒ 2BGR


### CRYSTAL STRUCTURE OF HIV-1 TAT DERIVED NONAPEPTIDES TAT(1-9) BOUND TO THE ACTIVE SITE OF DIPEPTIDYL PEPTIDASE IV (CD26)

**Characteristics**


Release Date: 27-Jan-2005 Exp. Method: X Ray Diffraction

**Classification**

 Resolution: 2.00 Å  
Hydrolase/complex

**Compound**


 Mol. Id: 1 Molecule: Dipeptidyl Peptidase Iv Fragment: E  
Domain Residues 29 766 Mol. Id: 2 Molecule: Hiv 1 Tat P  
Derived N Terminal Nonapeptide  
Weihs, W.A., Liu, J., Reutter, W., Saenger, W.

**Authors**
☒ 1W1I


### CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE IV (DPP-IV OR CD26) IN COMPLEX WITH ADENOSINE DEAMINASE

**Characteristics**

Release Date: 02-Sep-2004 Exp. Method: X Ray Diffraction

  
☐

**Classification**


**Compound**




**Authors**

**Resolution:** 3.03 Å

**Hydrolase/complex**

**Mol. Id: 1** **Molecule:** Dipeptidyl Peptidase Iv **Fragment:** E  
**Domain** 39 766 **Mol. Id: 2** **Molecule:** Adenosine Deaminas  
**Weihsfen, W.A., Liu, J., Reutter, W., Saenger, 'H.**

☒ 2BGN  
  
☐

**Characteristics**

**Classification**

**Compound**

**Authors**

**HIV-1 TAT PROTEIN DERIVED N-TERMINAL NONAPEPTIDE TRP2-TAT (1-9) BOUND TO THE ACTIVE SITE OF DIPEPTIDYL PEPTIDASE IV (CD26)**

**Release Date:** 27-Jan-2005 **Exp. Method:** X Ray Diffractio

**Resolution:** 3.15 Å

**Hydrolase/complex**

**Mol. Id: 1** **Molecule:** Dipeptidyl Peptidase Iv **Fragment:** E  
**Domain** Residues 39 766 **Mol. Id: 2** **Molecule:** Adenosine  
**Deaminase** **Mol. Id: 3** **Molecule:** Tat Protein **Fragment:**  
**Protein Derived N Terminal Nonapeptide Residues 1 9** **Mutati**  
**Weihsfen, W.A., Liu, J., Reutter, W., Saenger, 'H.**

## WEST Search History





DATE: Tuesday, June 06, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L12	(dipeptidyl peptidase IV or dipeptidylpeptidase IV or dipeptidyl peptidase-IV or dipeptidylpeptidase-IV or dpp-IV or dppIV or dpp IV) same (crystal or crystallization) and x-ray	3
		<i>DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L11	(dipeptidyl peptidase IV or dipeptidylpeptidase IV or dipeptidyl peptidase-IV or dipeptidylpeptidase-IV or dpp-IV or dppIV or dpp IV) same (crystal or crystallization) and x-ray	4
<input type="checkbox"/>	L10	(dipeptidyl peptidase IV or dipeptidylpeptidase IV or dipeptidyl peptidase-IV or dipeptidylpeptidase-IV or dpp-IV or dppIV or dpp IV)same crystal\$9	27
<input type="checkbox"/>	L9	(dipeptidyl adj1 peptidase adj1 IV or dpp adj1 IV)same crystal\$9	25
<input type="checkbox"/>	L8	(dipeptidyl adj1 peptidase adj1 IV or dpp adj2 IV)same crystal\$9	25
		<i>DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L7	L5 and x-ray	6
<input type="checkbox"/>	L6	L5	38
<input type="checkbox"/>	L5	(dipeptidyl adj1 peptidase adj1 IV or dpp adj2 IV)same crystal\$9	38
<input type="checkbox"/>	L4	(dipeptidylpeptidase adj3 IV or dpp adj2 IV)same crystal\$9	28
		<i>DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L3	L2	3
		<i>DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L2	(dipeptidylpeptidase adj3 IV or dpp adj2 IV)same crystal\$9	3
		<i>DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	(dipeptidyl adj3 peptidase adj3 IV or dpp adj3 IV)same crystal\$9	25

END OF SEARCH HISTORY

## Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

**Search Results - Record(s) 1 through 4 of 4 returned.**

☐ 1. Document ID: US 6355614 B1

L11: Entry 1 of 4

File: USPT

Mar 12, 2002

US-PAT-NO: 6355614

DOCUMENT-IDENTIFIER: US 6355614 B1

TITLE: Cyclic boroproline compounds

DATE-ISSUED: March 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wallner; Barbara P.	Weston	MA		

US-CL-CURRENT: 514/10; 514/249, 514/253.09

ABSTRACT:

Substantially pure preparations of cyclic boroProline compounds that bind, in cyclic or linear form, to CD26 are provided. Methods for using the cyclic compounds to stimulate the activation and/or proliferation of immune cells to achieve preselected normal in vivo levels of these cells also are provided. Evidence of the oral bioavailability and activity of a preferred cyclic compound, valine-prolineboronic acid (ValboroPro), also is provided.

8 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Keyword	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	---------	----------

☐ 2. Document ID: WO 2005119526 A1

L11: Entry 2 of 4

File: DWPI

Dec 15, 2005

DERWENT-ACC-NO: 2006-066968

DERWENT-WEEK: 200607

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: New crystalline composition of dipeptidyl peptidase IV, useful for treating diseases, e.g. diabetes, obesity, osteoporosis, arthritis, hypertension, atherosclerosis, ulcer, or inflammatory bowel syndrome

INVENTOR: QIU, X

PRIORITY-DATA: 2004US-576877P (June 3, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2005119526 A1</u>	December 15, 2005	E	151	G06F017/50

INT-CL (IPC): C07 K 14/00; G06 F 17/50

ABSTRACTED-PUB-NO: WO2005119526A

BASIC-ABSTRACT:

NOVELTY - A crystalline composition of the extracellular domain of mammalian dipeptidyl peptidase IV (DPP-IV) comprising one molecule per crystal asymmetric unit, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a polypeptide comprising the sequence of 766 amino acids (SEQ ID NO: 1) or its homologue or variant, where the molecules are arranged in a crystalline manner in a space group of P43212 so as to form a unit cell of dimensions a=b=68.7 Angstrom , c= 421.2 Angstrom and which diffracts X-rays for determination of the atomic coordinates of DPP-IV polypeptide to a resolution of 2.7 Angstrom ;

(2) a crystal of a protein-ligand molecule or molecular complex comprising: (i) a polypeptide with an amino acid sequence from Asp38 to Pro766 listed in SEQ ID NO: 1, or its homologue or variant; (ii) a ligand; and (iii) the crystal that diffracts X-rays for the determination of atomic coordinates of the protein-ligand complex to a resolution of greater than 2.7 Angstrom ;

(3) a method of designing a compound that binds to DPP-IV comprises the amino acid sequence spanning amino acids Gly31 to Pro766 listed in SEQ ID NO: 1, or its homologue or variant using the crystal above;

(4) a method for crystallizing a DPP-IV polypeptide molecule or molecular complex;

(5) a computer: (a) for producing a three-dimensional representation of a polypeptide with an amino acid sequence spanning amino acids Gly31 to Pro766 listed in SEQ ID NO: 1, or its homologue or variant; (b) for producing a three-dimensional representation of a molecule or molecular complex comprising the atomic coordinates having a root mean square deviation of less than 2.5, 2.0, 1.7, 1.5, 1.2, 1.0, 0.7, 0.5, or 0.2 Angstrom from the atomic coordinates for the carbon backbone atoms listed in the specification; or (c) for producing a three-dimensional representation of a molecule or molecular complex comprising a binding site defined by the structure coordinates given in the specification, or a the structural coordinates of a portion of the residues given in the specification, or the structural coordinates of one or more DPP-IV amino acids in SEQ ID NO: 1 selected from Glu205, Glu206, Tyr547, Ser630, Tyr631, Tyr662, Tyr666, Asp708, Asn710, or His740, the computer comprising: (i) a computer-readable data storage medium comprising a data storage material encoded with computer-readable data, where the data comprises the structure coordinates given in the specification, or their portions; (ii) a working memory for storing instructions for processing the computer-readable data; (iii) a central-processing unit coupled to the working memory and to the computer-readable data storage medium for processing the computer-machine readable data into the three-dimensional representation; and (iv) a display coupled to the central-processing unit for displaying the representation; and

(6) a method for identifying potential ligands for DPP-IV, or their homologues, analogues or variants.

ACTIVITY - Antidiabetic; Anorectic; Antilipemic; Osteopathic; Antiarthritic; Neuroprotective; Nephrotropic; Ophthalmological; Hypotensive; Antiarteriosclerotic; Antiulcer; Gastrointestinal-Gen; Antiinflammatory.

No biological data given.

MECHANISM OF ACTION - DPP-Inhibitor-IV.

USE - The crystal, composition, and method are useful for treating diseases, e.g. diabetes, obesity, lipidemia, osteoporosis, arthritis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, hypertension, atherosclerosis, ulcer, or inflammatory bowel syndrome.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: JP 2004173695 A, EP 1422293 A1

L11: Entry 3 of 4

File: DWPI

Jun 24, 2004

DERWENT-ACC-NO: 2004-413363

DERWENT-WEEK: 200441

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: New crystal of an extracellular domain of mammalian dipeptidyl-peptidase IV (DPP-IV) useful for identifying or designing inhibitors of DPP-IV activity

INVENTOR: HENNIG, M; LOEFFLER, B M ; THOMA, R

PRIORITY-DATA: 2002EP-0026367 (November 25, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2004173695 A</u>	June 24, 2004		214	C12N015/09
<u>EP 1422293 A1</u>	May 26, 2004	E	215	C12N009/48

INT-CL (IPC): A61 K 45/00; A61 P 3/04; A61 P 3/10; A61 P 35/00; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 9/48; C12 N 15/09; C12 Q 1/37; G01 N 33/15; G01 N 33/50

ABSTRACTED-PUB-NO: EP 1422293A

BASIC-ABSTRACT:

NOVELTY - A crystal (I) of extracellular domain of mammalian dipeptidyl-peptidase (DPP)-IV, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a co-crystal of the extracellular domain of mammalian DPP-IV and a ligand bound to its active site;

(2) a co-crystal of the extracellular domain of mammalian DPP-IV and a ligand bound

to an allosteric binding site;

(3) a co-crystal of the extracellular domain of mammalian DPP-IV and HgCl<sub>2</sub>;

(4) crystallizing (M1) mammalian DPP-IV, involves providing a buffered aqueous solution of pH 7-8.5 with a concentration of 7-22 mg/ml of the extracellular domain of mammalian DPP-IV, and growing crystals by vapor diffusion using a buffered reservoir solution with between 10-30% PEG and between 10-20% glycerol, where PEG has an average molecular weight between 1000-20000;

(5) co-crystallizing (M2) mammalian DPPIV and an active site ligand, involves providing a buffered aqueous solution of pH 7-8.5 with a concentration of 7-22 mg/ml of the extracellular domain of mammalian DPP-IV, adding a molar excess of the active site ligand to the aqueous solution of mammalian DPP-IV, and growing crystals by vapor diffusion using a buffered reservoir solution with between 10-30% PEG and between 10-20% glycerol, where PEG has an average molecular weight between 1000 and 20000;

(6) a crystal produced by (M1) and (M2);

(7) determining the three-dimensional structure of a crystallized extracellular domain of mammalian DPP-IV to a resolution of 3.5-2.1 Angstrom or better, involves crystallizing an extracellular domain of mammalian DPP-IV, and analyzing the extracellular domain of mammalian DPP-IV by X-ray diffraction to determine the three-dimensional structure of the crystallized extracellular domain of mammalian DPP-IV, where the three-dimensional structure of a crystallized extracellular domain of mammalian DPP-IV is determined to a resolution of 3.5-2.1 Angstrom or better;

(8) a machine-readable data storage medium comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using the data, displays a graphical three-dimensional representation of a molecule or molecular complex comprising at least a portion of the extracellular domain of mammalian DPP-IV comprising a fully defined sequence (S1) of 736 amino acids as given in the specification, where the extracellular domain comprising the ligand binding active site being defined by a set of points having a root mean square deviation of less than about 1.5 Angstrom from points representing the backbone atoms of the amino acids as represented by structure coordinates as given in the specification;

(9) a compound (II) identified by using (I);

(10) a pharmaceutical composition (III) comprising (I) and a carrier;

(11) an isolated nucleic acid sequence (IV) encoding the soluble extracellular domain of DPP-IV comprising a fully defined sequence (S2) of 2211 amino acids as given in the specification;

(12) a nucleic acid construct (V) comprising an expression vector and (IV);

(13) a host cell (VI) transformed with (V);

(14) producing the soluble extracellular domain of DPP-IV, involves culturing (VI) under conditions permitting the expression of the soluble extracellular domain of DPP-IV by (VI); and

(15) a polypeptide comprising the soluble extracellular domain of (S1).

ACTIVITY - Antidiabetic; Anorectic; Cytostatic.

MECHANISM OF ACTION - Inhibitor of DPP-IV (claimed). No supporting data is given.

USE - (I) is useful for identifying a compound that interacts with DPP-IV which involves generating (I) (a three-dimensional model of DPP-IV using atomic structure coordinates for DPP-IV as derived by X-ray diffraction from a crystal of DPP-IV) and a root mean square deviation from the backbone atoms of the amino acids of less than 1.5 Angstrom , and employing the three-dimensional model to design or select a compound that interacts with DPP-IV. The above method further involves obtaining the identified compound, and contacting the obtained compound with DPP-IV in order to determine the effect the compound has on DPP-IV activity. The compound interacts with the active site of DPP-IV. The compound interacts with an allosteric binding site of DPP-IV. The compound is an inhibitor of DPP-IV activity. The method is a computer-assisted method. (I) is useful for the identification and/or design of inhibitors of DPP-IV activity. (II) is useful as a therapeutic active substance, in particular for the treatment of diabetes type I, diabetes type II, IGT, obesity and cancer. (II) is useful for the manufacture of a medicament for the treatment of above mentioned disease (all claimed).

DESCRIPTION OF DRAWING(S) - The figure shows overall structure of dipeptidyl-peptidase (DPP)-IV.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	INDEX	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	----------

☐ 4. Document ID: JP 2005536995 W, WO 2004011640 A1, AU 2003253369 A1, EP 1525306 A1, US 20050260732 A1

L11: Entry 4 of 4

File: DWPI

Dec 8, 2005

DERWENT-ACC-NO: 2004-156830

DERWENT-WEEK: 200580

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: New crystal of dipeptidyl peptidase IV capable of analyzing its three-dimensional structure, useful for designing, identifying, evaluating or searching an effector of the dipeptidyl peptidase IV

INVENTOR: HIRAMATSU, H; KYONO, K ; SHIMA, H ; SUGIYAMA, S

PRIORITY-DATA: 2002US-398761P (July 29, 2002), 2005US-0522789 (January 28, 2005)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2005536995 W</u>	December 8, 2005		110	C12N009/48
<u>WO 2004011640 A1</u>	February 5, 2004	E	342	C12N009/48
<u>AU 2003253369 A1</u>	February 16, 2004		000	C12N009/48
<u>EP 1525306 A1</u>	April 27, 2005	E	000	C12N009/48
<u>US 20050260732 A1</u>	November 24, 2005		000	C12N009/64

INT-CL (IPC): A61 K 45/00; A61 P 3/10; A61 P 19/02; A61 P 25/00; A61 P 29/00; A61 P 31/18; A61 P 35/00; A61 P 37/02; A61 P 43/00; C07 K 14/705; C12 N 9/48; C12 N 9/64; C12 N 15/09; C12 Q 1/37; G01 N 23/20; G01 N 33/15; G01 N 33/48; G01 N 33/50; G01 N 33/573; G06 F 19/00

ABSTRACTED-PUB-NO: WO2004011640A



## BASIC-ABSTRACT:

NOVELTY - A crystal of a dipeptidyl peptidase IV, which is sufficient to ensure a resolution capable of analyzing its three-dimensional structure up to the side chain level by X-ray crystallographic structural analysis, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a three-dimensional structural coordinate of a dipeptidyl peptidase IV comprising the structural coordinate, which is fully defined in the specification or a structural coordinate different from the structural coordinate given in the specification;
- (2) a three-dimensional structural coordinate of a region in a dipeptidyl peptidase IV comprising the three-dimensional structural coordinate of the region selected from: (a) the region of Ser 630, Asp 708 and His 740 in the amino acid sequence comprising 766 amino acids (SEQ ID NO. 2), and all or a part of a group of the amino acid residues located in the adjacent area of Ser 630, Asp 708 and His 740 in the structural coordinate given in the specification or the three-dimensional structure model defined by the structural coordinate; (b) the region of Ser 630, Asp 708 and His 740 in SEQ ID NO: 2, and all or a part of a group of the amino acid residues comprising amino acids capable of maintaining physicochemical characteristics physiologically equivalent to each of amino acids in the group of the amino acid residues located in the adjacent area of Ser 630, Asp 708 and His 740; (c) the region of a group of amino acid residues comprising amino acids capable of maintaining physicochemical characteristics physiologically equivalent to Ser 630, Asp 708 and His 740 in SEQ ID NO: 2, and all or a part of a group of the amino acid residues located adjacent area of the group of the amino acid residues in the structural coordinate given in the specification or the three-dimensional structure model defined by the structural coordinate; and (d) the region of a group of amino acid residues comprising amino acids capable of maintaining physicochemical characteristics physiologically equivalent to Ser 630, Asp 708 and His 740 in SEQ ID NO: 2, and all or a part of a group of amino acid residues comprising amino acids capable of maintaining physicochemical characteristics physiologically equivalent to each of the amino acids in the group of the amino acid residues located in the adjacent area of the group of the amino acids, in the structural coordinate given in the specification or the three-dimensional structure model defined by the structural coordinate, wherein the region in the dipeptidyl peptidase IV is a region involved in binding or interaction between the dipeptidyl peptidase IV and an effector of the dipeptidyl peptidase IV;
- (3) a method for obtaining a three-dimensional coordinate of a homologue protein of a dipeptidyl peptidase IV;
- (4) a method for obtaining a three-dimensional structural coordinate of a crystal of a complex of a dipeptidyl peptidase IV and an effector of the dipeptidyl peptidase;
- (5) a method for identifying pharmacophore of an effector of the dipeptidyl peptidase IV;
- (6) a method for designing, identifying, evaluating or searching an effector of a dipeptidyl peptidase IV;
- (7) an effector of the dipeptidyl peptidase IV obtainable by the method above; and
- (8) a program and a medium for use of the three-dimensional structural coordinate, wherein all and/or a part of the three-dimensional structural coordinate is recorded.

ACTIVITY - Immunomodulatory; Antidiabetic; Antiinflammatory; Neuroprotective; Antithyroid; Antirheumatic; Antiarthritic; Anti-HIV; Cytostatic.

MECHANISM OF ACTION - Dipeptidyl peptidase IV effector.

USE - The crystal of a dipeptidyl peptidase IV is useful for providing a three-dimensional structural coordinate as the information for designing, identifying, evaluating or searching an effector of the dipeptidyl peptidase IV. The effector is useful as modulatory agent of immune response and as a therapeutic or prophylactic agent for diabetes, inflammation, multiple sclerosis, Graves' disease, chronic rheumatoid arthritis, AIDS or cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms	Documents
(dipeptidyl peptidase IV or dipeptidylpeptidase IV or dipeptidyl peptidase-IV or dipeptidylpeptidase-IV or dpp-IV or dppIV or dpp IV) same (crystal or crystallization) and x-ray	4

**Display Format:**[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

## Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

### Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20060024313 A1

L12: Entry 1 of 3

File: PGPB

Feb 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060024313

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060024313 A1

TITLE: Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases

PUBLICATION-DATE: February 2, 2006

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Chen; Xin	Miaoli		TW
Chen; Yuan-Shou	Taipei City		TW

US-CL-CURRENT: 424/146.1; 435/226, 435/320.1, 435/325, 435/69.1, 530/388.26,  
536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 2. Document ID: US 20050261271 A1

L12: Entry 2 of 3

File: PGPB

Nov 24, 2005

PGPUB-DOCUMENT-NUMBER: 20050261271

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050261271 A1

TITLE: Dipeptidyl peptidase inhibitors

PUBLICATION-DATE: November 24, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Feng, Jun	Carlsbad	CA	US
Gwaltney, Stephen L.	San Diego	CA	US
Stafford, Jeffrey A.	San Diego	CA	US
Zhang, Zhiyuan	San Diego	CA	US
Elder, Bruce J.	Wynantskill	NY	US
Isbester, Paul K.	Castleton	NY	US

Palmer, Grant J.	Clifton Park	NY	US
Salsbury, Jonathon S.	Albany	NY	US
Ulysse, Luckner G.	Albany	NY	US

US-CL-CURRENT: [514/210.2](#); [514/217.05](#), [514/217.06](#), [514/241](#), [514/275](#), [540/601](#),  
[544/209](#), [544/331](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 3. Document ID: US 20050260732 A1

L12: Entry 3 of 3

File: PGPB

Nov 24, 2005

PGPUB-DOCUMENT-NUMBER: 20050260732

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050260732 A1

TITLE: Three-dimensional structure of dipeptidyl peptidase IV

PUBLICATION-DATE: November 24, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Hiramatsu, Hajime	Osaka		JP
Kyono, Kiyoshi	Osaka		JP
Shima, Hideaki	Hyogo		JP
Sugiyama, Shigeru	Nara		JP

US-CL-CURRENT: [435/226](#); [702/19](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
(dipeptidyl peptidase IV or dipeptidylpeptidase IV or dipeptidyl peptidase-IV or dipeptidylpeptidase-IV or dpp-IV or dppIV or dpp IV) same (crystal or crystallization) and x-ray	3

Display Format:

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

**STN Search**

10/722,049

FILE 'HOME' ENTERED AT 14:11:13 ON 06 JUN 2006

=&gt; file .nash

=&gt; s (dpp-IV or ddp IV or dppiv) and crystal?

L1 25 FILE MEDLINE  
L2 37 FILE CAPLUS  
L3 36 FILE SCISEARCH  
L4 2 FILE LIFESCI  
L5 18 FILE BIOSIS  
L6 19 FILE EMBASE

TOTAL FOR ALL FILES

L7 137 (DPP-IV OR DDP IV OR DPPIV) AND CRYSTAL?

=&gt; s l7 not 2004-2006/py

TOTAL FOR ALL FILES

L14 33 L7 NOT 2004-2006/PY

=&gt; dup rem l14

PROCESSING COMPLETED FOR L14

L15 12 DUP REM L14 (21 DUPLICATES REMOVED)

=&gt; d ibib abs 1-12

L15 ANSWER 1 OF 12 MEDLINE on STN

ACCESSION NUMBER: 2003275428 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 12801240

TITLE: 1-[[[3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

AUTHOR: Villhauer Edwin B; Brinkman John A; Naderi Goli B; Burkey Bryan F; Dunning Beth E; Prasad Kapa; Mangold Bonnie L; Russell Mary E; Hughes Thomas E

CORPORATE SOURCE: Novartis Institute for Biomedical Research, One Health Plaza, East Hanover, New Jersey 07936, USA..  
edwin.villhauer@pharma.novartis.com

SOURCE: Journal of medicinal chemistry, (2003 Jun 19) Vol. 46, No. 13, pp. 2774-89.

Journal code: 9716531. ISSN: 0022-2623.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200307

ENTRY DATE: Entered STN: 13 Jun 2003

Last Updated on STN: 16 Jul 2003

Entered Medline: 15 Jul 2003

AB Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and structure-activity relationship of a new DPP-IV inhibitor class, N-substituted-glycyl-2-cyanopyrrolidines, are described as well as the path that led from clinical development compound 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728, 8c) to its follow-up, 1-[[[3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP-LAF237, 12j). The pharmacological profile of 12j in obese Zucker fa/fa rats along with pharmacokinetic profile comparison of 8c and 12j in normal cynomolgus monkeys is discussed. The results suggest that 12j is a potent, stable, selective DPP-IV inhibitor possessing excellent oral bioavailability and potent antihyperglycemic activity with potential for once-a-day administration.

L15 ANSWER 2 OF 12 MEDLINE on STN

DUPLICATE 1

ACCESSION NUMBER: 2003373331 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 12906826

TITLE: Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV.

AUTHOR: Thoma Ralf; Loffler Bernd; Stihle Martine; Huber Walter; Ruf Armin; Hennig Michael

CORPORATE SOURCE: F. Hoffmann-La Roche AG, Pharma Research Discovery, 4070 Basel, Switzerland.

SOURCE: Structure (Cambridge, Mass. : 2001), (2003 Aug) Vol. 11,  
No. 8, pp. 947-59.  
Journal code: 101087697. ISSN: 0969-2126.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: PDB-1NU6; PDB-1NU8  
ENTRY MONTH: 200404  
ENTRY DATE: Entered STN: 9 Aug 2003  
Last Updated on STN: 15 Apr 2004  
Entered Medline: 14 Apr 2004

AB Inhibition of dipeptidyl peptidase IV (DPP-IV), the main glucagon-like peptide 1 (GLP1)-degrading enzyme, has been proposed for the treatment of type II diabetes. We expressed and purified the ectodomain of human DPP-IV in *Pichia pastoris* and determined the X-ray structure at 2.1 Å resolution. The enzyme consists of two domains, the catalytic domain, with an alpha/beta hydrolase fold, and a beta propeller domain with an 8-fold repeat of a four-strand beta sheet motif. The beta propeller domain contributes two important functions to the molecule that have not been reported for such structures, an extra beta sheet motif that forms part of the dimerization interface and an additional short helix with a double Glu sequence motif. The Glu motif provides recognition and a binding site for the N terminus of the substrates, as revealed by the complex structure with diprotin A, a substrate with low turnover that is trapped in the tetrahedral intermediate of the reaction in the crystal.

L15 ANSWER 3 OF 12 MEDLINE on STN DUPLICATE 2  
ACCESSION NUMBER: 2003132018 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 12646248  
TITLE: The structure and function of human dipeptidyl peptidase  
IV, possessing a unique eight-bladed beta-propeller fold.  
AUTHOR: Hiramatsu Hajime; Kyono Kiyoshi; Higashiyama Yutaka;  
Fukushima Chiaki; Shima Hideaki; Sugiyama Shigeru; Inaka  
Koji; Yamamoto Atsushi; Shimizu Ryo  
CORPORATE SOURCE: Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd.,  
3-16-86 Kashima, Yodogawa-ku, Osaka 532-8505, Japan.  
SOURCE: Biochemical and biophysical research communications, (2003  
Mar 21) Vol. 302, No. 4, pp. 849-54.  
Journal code: 0372516. ISSN: 0006-291X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200305  
ENTRY DATE: Entered STN: 21 Mar 2003  
Last Updated on STN: 14 May 2003  
Entered Medline: 13 May 2003

AB Dipeptidyl peptidase IV (DPPIV) is a serine protease, a member of the prolyl oligopeptidase (POP) family, and has been implicated in several diseases. Therefore, the development of DPPIV selective inhibitors, which are able to control the biological function of DPPIV, is important. We determined the crystal structure of human DPPIV at 2.6 Å resolution. The molecule consists of a unique eight-bladed beta-propeller domain in the N-terminal region and a serine protease domain in the C-terminal region. Also, the large "cave" structure, which is thought to control the access of the substrate, is found on the side of the beta-propeller fold. Comparison of the overall amino acid sequence between human DPPIV and POP shows low homology (12.9%). In this paper, we report the structure of human DPPIV, especially focusing on a unique eight-bladed beta-propeller domain. We also discuss the way for the access of the substrate to this domain.

L15 ANSWER 4 OF 12 MEDLINE on STN DUPLICATE 3  
ACCESSION NUMBER: 2003083668 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 12595736  
TITLE: Crystallization and preliminary X-ray study of  
human dipeptidyl peptidase IV (DPPIV).  
AUTHOR: Hiramatsu Hajime; Kyono Kiyoshi; Shima Hideaki; Fukushima  
Chiaki; Sugiyama Shigeru; Inaka Koji; Yamamoto Atsushi;  
Shimizu Ryo  
CORPORATE SOURCE: Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd,  
3-16-89 Kashima, Yodogawa-ku, Osaka 532-8505, Japan.  
SOURCE: Acta crystallographica. Section D, Biological

crystallography, (2003 Mar) Vol. 59, No. Pt 3, pp. 595-6.  
Electronic Publication: 2003-02-21.  
Journal code: 9305878. ISSN: 0907-4449.

PUB. COUNTRY: Denmark  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200310  
ENTRY DATE: Entered STN: 22 Feb 2003  
Last Updated on STN: 8 Oct 2003  
Entered Medline: 7 Oct 2003

AB Human DPPIV has been expressed in the baculovirus system and purified and crystallized using the hanging-drop method. A crystal was obtained from 180 mM Gly-NaOH buffer pH 9.5 containing 18% PEG 4000 and 180 mM sodium acetate. The crystal belongs to the orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a = 118.04, b = 125.92, c = 136.84 Å, and diffracts beyond 2.6 Å resolution. There are two molecules per asymmetric unit, indicating a solvent content of 57.6%.

L15 ANSWER 5 OF 12 MEDLINE on STN DUPLICATE 4

ACCESSION NUMBER: 2002728574 IN-PROCESS Full-text  
DOCUMENT NUMBER: PubMed ID: 12483204  
TITLE: Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.  
AUTHOR: Rasmussen Hanne B; Branner Sven; Wiberg Finn C; Wagtmann Nicolai  
CORPORATE SOURCE: Protein Chemistry, Research and Development, Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark.  
SOURCE: Nature structural biology, (2003 Jan) Vol. 10, No. 1, pp. 19-25.  
Journal code: 9421566. ISSN: 1072-8368.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals  
ENTRY DATE: Entered STN: 20 Dec 2002  
Last Updated on STN: 17 Dec 2003

AB Dipeptidyl peptidase IV (DPP-IV/CD26) is a multifunctional type II transmembrane serine peptidase. This enzyme contributes to the regulation of various physiological processes, including blood sugar homeostasis, by cleaving peptide hormones, chemokines and neuropeptides. We have determined the 2.5 Å structure of the extracellular region of DPP-IV in complex with the inhibitor valine-pyrrolidide. The catalytic site is located in a large cavity formed between the alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain. Both domains participate in inhibitor binding. The structure indicates how substrate specificity is achieved and reveals a new and unexpected opening to the active site.

L15 ANSWER 6 OF 12 MEDLINE on STN DUPLICATE 5

ACCESSION NUMBER: 2002426880 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 12182835  
TITLE: Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells.  
AUTHOR: Dobers Jorg; Zimmermann-Kordmann Martin; Leddermann Melanie; Schewe Tina; Reutter Werner; Fan Hua  
CORPORATE SOURCE: Institut fur Molekularbiologie und Biochemie, Fachbereich Humanmedizin, Freie Universitat Berlin, Arnimallee 22, D-14195 Berlin-Dahlem, Germany.  
SOURCE: Protein expression and purification, (2002 Aug) Vol. 25, No. 3, pp. 527-32.  
Journal code: 9101496. ISSN: 1046-5928.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200303  
ENTRY DATE: Entered STN: 17 Aug 2002  
Last Updated on STN: 13 Mar 2003  
Entered Medline: 12 Mar 2003

AB The human dipeptidyl peptidase IV/CD26 (DPPIV/CD26) is a multifunctional type-II membrane bound glycoprotein. As a receptor of collagen I and fibronectin it mediates cell-cell and cell-matrix adhesion, and by interacting with extracellular adenosine deaminase and CD45 it is involved in regulatory and costimulatory events in the immune system. DPPIV/CD26 has a very distinct substrate specificity, and is potentially capable of truncating many cytokines, chemokines, and peptide hormones. In this study, we describe the overexpression, purification, and characterization of human DPPIV/CD26 in *Spodoptera frugiperda* (Sf9) cells, using the baculovirus system. Overexpression of DPPIV/CD26 was confirmed by measurement of its peptidase specificity, SDS-PAGE, and Western blot analyses. Expression rates were between 6.4 and 17.6 mg protein per liter suspension culture ( $1.5 \times 10^9$  cells). The N-linked oligosaccharide composition was examined and compared with that of mammalian cell-expressed DPPIV/CD26. Two-step purification by immunoaffinity chromatography and size-exclusion fast protein liquid chromatography (SE-FPLC) led to highly stable protein with significant peptidase activity. A subsequent gel filtration step on a Superdex 200 column yielded 2mg homogeneous dimeric DPPIV/CD26 (per liter insect cell culture) for crystallographic studies. Protein homogeneity was confirmed by silver staining of non-denaturing PAGE gels and by MALDI-TOF analysis of tryptic peptides.

L15 ANSWER 7 OF 12 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2002:302127 SCISEARCH Full-text

THE GENUINE ARTICLE: 536QM

TITLE: Threading with chemostructural restrictions method for predicting fold and functionally significant residues: Application to dipeptidylpeptidase IV (DPP-IV)

AUTHOR: Reva B (Reprint); Finkelstein A; Topiol S

CORPORATE SOURCE: Discovery Partners Int, Computat Div, Suite 645, 2 Execut Dr, Ft Lee, NJ 07024 USA (Reprint); Novartis Inst Biomed Res, Summit, NJ USA; Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia

COUNTRY OF AUTHOR: USA; Russia

SOURCE: PROTEINS-STRUCTURE FUNCTION AND GENETICS, (1 MAY 2002)  
Vol. 47, No. 2, pp. 180-193.  
ISSN: 0887-3585.

PUBLISHER: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 52

ENTRY DATE: Entered STN: 19 Apr 2002

Last Updated on STN: 19 Apr 2002

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB We present a new method for more accurate modeling of protein structure, called threading with chemostructural restrictions. This method addresses those cases in which a target sequence has only remote homologues of known structure for which sequence comparison methods cannot provide accurate alignments. Although remote homologues cannot provide an accurate model for the whole chain, they can be used in constructing practically useful models for the most conserved-and often the most interesting-part of the structure. For many proteins of interest, one can suggest certain chemostructural patterns for the native structure based on the available information on the structural superfamily of the protein, the type of activity, the sequence location of the functionally significant residues, and other factors. We use such patterns to restrict (1) a number of possible templates, and (2) a number of allowed chain conformations on a template. The latter restrictions are imposed in the form of additional template potentials (including terms acting as sequence anchors) that act on certain residues. This approach is tested on remote homologues of alpha/beta-hydrolases that have significant structural similarity in the positions of their catalytic triads. The study shows that, in spite of significant deviations between the model and the native structures, the surroundings of the catalytic triad (positions of C-alpha atoms of 20-30 nearby residues) can be reproduced with accuracy of 2-3 Angstrom. We then apply the approach to predict the structure of dipeptidylpeptidase IV (DPP-IV). Using experimentally available data identifying the catalytic triad residues of DPP-IV (David et al., J Biol Chem 1993;268:1724717252); we predict a model structure of the catalytic domain of DPP-TV based on the 3D fold of prolyl oligopeptidase (Fulop et al., Cell 1998;94:161-170) and use this structure for modeling the interaction of DPP-IV with inhibitor.



L15 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:723704 CAPLUS Full-text

DOCUMENT NUMBER: 136:2627

TITLE: Sulphostin, a potent inhibitor for dipeptidyl  
peptidase IV from Streptomyces sp. MK251-43F3

AUTHOR(S): Akiyama, Tetsuo; Abe, Masatoshi; Harada, Shigeko;  
Kojima, Fukiko; Sawa, Ryuichi; Takahashi, Yoshikazu;  
Naganawa, Hiroshi; Homma, Yoshiko; Hamada, Masa;  
Yamaguchi, Akihito; Aoyagi, Takaaki; Muraoka,  
Yasuhiko; Takeuchi, Tomio

CORPORATE SOURCE: Institute of Microbial Chemistry, Tokyo, 141-0021,  
Japan

SOURCE: Journal of Antibiotics (2001), 54(9), 744-746

CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The production, isolation, and structure elucidation of isolated sulfostin (1) and its  
epimer were presented. Sulfostin was isolated from the culture broth of Streptomyces sp.  
MK251-43F3 together with its epimer, which was found to be formed during the isolation  
process. The fermentation process of producing sulfostin was extremely hard due to low  
productivity, tedious isolation procedure, and unavoidable epimerization during the  
isolation process. Chemical syntheses of sulfostin and its three diastereomers was  
successfully obtained. The X-ray crystal anal. of synthesized 1 showed that the absolute  
configurations of the C-3 and the phosphorus atoms of 1 were S and R, resp. The structure  
of sulfostin was found to be 3(S)-amino-1-[(R)-amino(sulfoamino)phosphinyl]-2-piperidone.  
Sulfostin showed inhibitory activities of dipeptidyl peptidase IV (DPP-IV) with dose-  
dependent manner, and the IC50 value was 6 ng/mL, which was determined to be 100-fold  
stronger than that of diprotin A (a known DPP-IV inhibitor).

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 12 MEDLINE on STN DUPLICATE 6

ACCESSION NUMBER: 1999045629 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 9826645

TITLE: Inhibition of dipeptidyl peptidase IV by  
fluoroolefin-containing N-peptidyl-O-hydroxylamine  
peptidomimetics.

AUTHOR: Lin J; Toscano P J; Welch J T

CORPORATE SOURCE: Department of Chemistry, University at Albany, Albany, NY  
12222, USA.

CONTRACT NUMBER: A133690

SOURCE: Proceedings of the National Academy of Sciences of the  
United States of America, (1998 Nov 24) Vol. 95, No. 24,  
pp. 14020-4.

Journal code: 7505876. ISSN: 0027-8424.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199812

ENTRY DATE: Entered STN: 15 Jan 1999

Last Updated on STN: 15 Jan 1999


Entered Medline: 28 Dec 1998

AB Dipeptidyl peptidase IV (EC 3.4.14.5; DPP IV), also known as the leukocyte differentiation  
antigen CD26 when found as an extracellular membrane-bound proline specific serine  
protease, cleaves a dipeptide from the N terminus of a polypeptide chain containing a  
proline residue in the penultimate position. Here we report that known (Z)-Ala-psi[CF=C]-  
Pro dipeptide isosteres 1 and 2, which contain O-acylhydroxylamines, were isolated as  
diastereomeric pairs u-1, l-1, and l-2. The effect of each diastereomeric pair as an  
inhibitor of human placental dipeptidyl peptidase DPP IV has been examined. The  
inhibition of DPP IV by these compounds is rapid and efficient. The diastereomeric pair  
u-1 exhibits very potent inhibitory activity with a Ki of 188 nM. Fluoroolefin containing  
N-peptidyl-O-hydroxylamine peptidomimetics, by virtue of their inhibitory potency and  
stability, are superior to N-peptidyl-O-hydroxylamine inhibitors derived from an Ala-Pro  
dipeptide.

L15 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 1995:183432 CAPLUS Full-text

DOCUMENT NUMBER: 122:240402  
 TITLE: Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond  
 AUTHOR(S): Snow, Roger J.; Bachovchin, William W.; Barton, Randall W.; Campbell, Scot J.; Coutts, Simon J.; Freeman, Dorothy M.; Gutheil, William G.; Kelly, Terence A.; Kennedy, Charles A.; et al.  
 CORPORATE SOURCE: Department of Medicinal Chemistry Pharmacology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 06877, USA  
 SOURCE: Journal of the American Chemical Society (1994), 116(24), 10860-9  
 CODEN: JACSAT; ISSN: 0002-7863  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB The proline boronic acid dipeptides I (R = H-Ala, H-Pro, H-Val) are very potent inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV or CD26), found on the surface of T-cells, and are a new class of immunosuppressants. The efficient synthesis of the free boronic acids as single enantiomers is described, and the absolute configuration determined. I loses DPP IV inhibitory activity in solution: this is shown to be due to the reversible formation of a cyclic species analogous to a diketopiperazine, containing a B-N bond. The cyclic compds., both as the free boronic acids and as the pinanediol esters, were isolated and characterized by <sup>1</sup>H and <sup>11</sup>B NMR, and in the case of II, by x-ray crystallog. The cyclization is pH dependent, with the open form favored at low pH, while the cyclic form predominates at neutral pH. Both the rate and extent of cyclization depend on the N-terminal amino acid. The rates of cyclization have been measured by <sup>1</sup>H NMR and shown to correlate with the decrease in DPP IV inhibitory activity. I (R = H-Val) cyclizes more slowly, and to a lesser extent than I (R = H-Ala, H-Pro), which is predicted to lead to greater immunosuppressive potency in vivo.

L15 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:456711 CAPLUS Full-text  
 TITLE: Discovery, Structure-Activity Relationship, and Pharmacological Evaluation of (5-Substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors  
 AUTHOR(S): Pei, Zhonghua; Li, Xiaofeng; Longenecker, Kenton; von Geldern, Thomas W.; Wiedeman, Paul E.; Lubben, Thomas H.; Zinker, Bradley A.; Stewart, Kent; Ballaron, Stephen J.; Stashko, Michael A.; Mika, Amanda K.; Beno, David W. A.; Long, Michelle; Wells, Heidi; Kempf-Grote, Anita J.; Madar, David J.; McDermott, Todd S.; Bhagavatula, Lakshmi; Fickes, Michael G.; Pireh, Daisy; Solomon, Larry R.; Lake, Marc R.; Edalji, Rohinton; Fry, Elizabeth H.; Sham, Hing L.; Trevillyan, James M.  
 CORPORATE SOURCE: Metabolic Disease Research, Advanced Technology, Departments of Exploratory Pharmacokinetics and Pharmaceuticals and Process Chemistry Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064-3500, USA

SOURCE: Journal of Medicinal Chemistry ACS ASAP  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro) analogs was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes and obesity. X-ray crystallog. data show that these inhibitors bind to the catalytic site of DPPIV with the cyano group forming a covalent bond with the serine residue of DPPIV. The C5-substituents make various interactions with the enzyme and affect potency, chemical stability, selectivity, and PK properties of the inhibitors. Optimized analogs are extremely potent with subnanomolar  $K_i$ 's, are chemical stable, show very little potency decrease in the presence of plasma, and exhibit more than 1,000-fold selectivity against related peptidases. The best compds. also possess good PK and are efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:492547 CAPLUS Full-text

TITLE: Crystal Structures of DPP-IV (CD26) from Rat Kidney Exhibit Flexible Accommodation of Peptidase-Selective Inhibitors  
AUTHOR(S): Longenecker, Kenton L.; Stewart, Kent D.; Madar, David J.; Jakob, Clarissa G.; Fry, Elizabeth H.; Wilk, Sherwin; Lin, Chun W.; Ballaron, Stephen J.; Stashko, Michael A.; Lubben, Thomas H.; Yong, Hong; Pireh, Daisy; Pei, Zhonghua; Basha, Fatima; Wiedeman, Paul E.; von Geldern, Thomas W.; Trevillyan, James M.; Stoll, Vincent S.

SOURCE: Biochemistry ACS ASAP  
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Dipeptidyl peptidase IV (DPP-IV) belongs to a family of serine peptidases, and due to its indirect regulatory role in plasma glucose modulation, DPP-IV has become an attractive pharmaceutical target for diabetes therapy. DPP-IV inactivates the glucagon-like peptide (GLP-1) and several other naturally produced bioactive peptides that contain preferentially a proline or alanine residue in the second amino acid sequence position by cleaving the N-terminal dipeptide. To elucidate the details of the active site for structure-based drug design, we crystallized a natural source preparation of DPP-IV isolated from rat kidney and determined its three-dimensional structure using X-ray diffraction techniques. With a high degree of similarity to structures of human DPP-IV, the active site architecture provides important details for the design of inhibitory compds., and structures of inhibitor-protein complexes offer detailed insight into three-dimensional structure-activity relationships that include a conformational change of Tyr548. Such accommodation is exemplified by the response to chemical substitution on 2-cyanopyrrolidine inhibitors at the 5 position, which conveys inhibitory selectivity for DPP-IV over closely related homologues. A similar conformational change is also observed in the complex with an unrelated synthetic inhibitor containing a xanthine core that is also selective for DPP-IV. These results suggest the conformational flexibility of Tyr548 is unique among protein family members and may be utilized in drug design to achieve peptidase selectivity.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y